<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hims-Hers-Health-Inc-US4330001060">Hims &amp; Hers Health Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">24/7 Wall Street</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://247wallst.com/investing/2026/04/21/did-amazon-just-wreck-all-of-hims-hers-upside-potential/?utm_source=snapi">Did Amazon Just Wreck All of Hims &amp; Hers Upside Potential?</a>
    </div>

      <div class="me-0 me-md-5">
        The GLP-1 weight-loss category exploded into a multi-billion-dollar opportunity that blends medication access with ongoing patient support.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hims-Hers-Health-Inc-US4330001060">Hims &amp; Hers Health Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">24/7 Wall Street</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://247wallst.com/investing/2026/04/20/hims-hers-rallies-9-as-investors-bet-big-on-peptide-pipeline-and-novo-nordisk-deal/?utm_source=snapi">Hims &amp; Hers Rallies 9% as Investors Bet Big on Peptide Pipeline and Novo Nordisk Deal</a>
    </div>

      <div class="me-0 me-md-5">
        Hims &amp; Hers Health (NYSE:HIMS) shares are up 9% in early trading Monday, climbing from $28.82 to $31 and change as investors pile into the stock ahead of a May 11 earnings report.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hims-Hers-Health-Inc-US4330001060">Hims &amp; Hers Health Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">The Motley Fool</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.fool.com/coverage/stock-market-today/2026/04/16/stock-market-today-april-16-hims-hers-health-jumps-on-fda-review-of-compounded-peptide-therapies/">Stock Market Today, April 16: Hims &amp; Hers Health Jumps on FDA Review of Compounded Peptide Therapies</a>
    </div>

      <div class="me-0 me-md-5">
        Expand NYSE: HIMS Hims &amp; Hers Health Today&#39;s Change (11.28%) $2.74 Current Price $27.03 Key Data Points Market Cap $5.5B Day&#39;s Range $24.77 - $27.81 52wk Range $13.74 - $70.43 Volume 2.5M Avg Vol 35M Gross Margin 60.86% Hims &amp; Hers Health (HIMS +11.28%), a consumer-focused telehealth platform offering prescription and non-prescription health products, closed Thursday at $26.98, up 11.07%. The s...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hims-Hers-Health-Inc-US4330001060">Hims &amp; Hers Health Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">CNBC</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.cnbc.com/2026/04/16/rfk-jr-peptides-hims-hers-glp-1.html">RFK Jr.&#39;s peptide policy could boost Hims &amp; Hers as its GLP-1 business evolves</a>
    </div>

      <div class="me-0 me-md-5">
        Investors are starting to focus on what will replace compounded GLP-1 driven growth for telehealth companies like Hims &amp; Hers Health. Peptides are gaining attention as a potential new growth vector, despite clinical evidence for efficacy being limited.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hims-Hers-Health-Inc-US4330001060">Hims &amp; Hers Health Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Proactive Investors</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.proactiveinvestors.com/companies/news/1090704?SNAPI">Hims &amp; Hers shares jump as FDA begins review of restricted peptide compounds</a>
    </div>

      <div class="me-0 me-md-5">
        Shares of Hims &amp; Hers Health (NYSE:HIMS) rose more than 8% to about $26 after the US Food and Drug Administration (FDA) moved to begin a formal review process that could eventually reshape the regulatory status of several wellness peptides used in compounding pharmacies. The FDA announced it will hold meetings on July 23 and 24 with its Pharmacy Compounding Advisory Committee to discuss whether...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hims-Hers-Health-Inc-US4330001060">Hims &amp; Hers Health Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Reuters</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.reuters.com/business/healthcare-pharmaceuticals/hims-rises-fda-considers-broader-peptides-access-analysts-see-long-term-win-2026-04-16/">Hims rises as FDA considers broader peptides access; analysts see long-term win</a>
    </div>

      <div class="me-0 me-md-5">
        Shares of Hims &amp; Hers Health rose more than 7% on Thursday as analysts said the U.S. drug regulator&#39;s consideration to allow compounding pharmacies to ​manufacture popular peptides could benefit the telehealth firm in the long run.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hims-Hers-Health-Inc-US4330001060">Hims &amp; Hers Health Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Invezz</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://invezz.com/news/2026/04/16/hims-hers-surges-4-as-peptide-policy-shift-unlocks-growth/?utm_source=snapi">Hims &amp; Hers surges 4% as peptide policy shift unlocks growth</a>
    </div>

      <div class="me-0 me-md-5">
        Shares of Hims &amp; Hers Health moved sharply higher on Thursday, extending gains from the previous session after a significant regulatory shift signaled new opportunities in the peptide market. The stock rose about 4% to $25.28 on Thursday morning after closing up 14% on Wednesday, as investors reacted to comments from Robert F.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/Hims-Hers-Health-Inc-US4330001060">Hims &amp; Hers Health Inc.</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">24/7 Wall Street</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://247wallst.com/investing/2026/04/16/bofa-raises-hims-hers-target-to-25-as-fda-takes-a-step-toward-wellness-peptides-is-a-new-revenue-boom-coming/?utm_source=snapi">BofA Raises Hims &amp; Hers Target to $25 as FDA Takes a Step Toward Wellness Peptides: Is a New Revenue Boom Coming?</a>
    </div>

      <div class="me-0 me-md-5">
        Hims &amp; Hers Health (NYSE:HIMS) just got a fresh look from Bank of America, which raised its price target on the stock to $25 from $21 while maintaining a Neutral rating.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
</div>
</template></turbo-stream>